Research Analysts Offer Predictions for Accolade, Inc.’s FY2026 Earnings (NASDAQ:ACCD)

Accolade, Inc. (NASDAQ:ACCD) – Equities research analysts at William Blair issued their FY2026 EPS estimates for Accolade in a research note issued to investors on Thursday, April 25th. William Blair analyst R. Daniels anticipates that the company will post earnings per share of ($1.01) for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Accolade’s current full-year earnings is ($1.20) per share.

A number of other research analysts have also recently weighed in on ACCD. Raymond James lifted their target price on shares of Accolade from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Tuesday, January 9th. Stifel Nicolaus decreased their price target on shares of Accolade from $15.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, April 22nd. Leerink Partnrs reiterated an “outperform” rating on shares of Accolade in a research note on Monday, February 26th. SVB Leerink started coverage on shares of Accolade in a research note on Monday, February 26th. They issued an “outperform” rating and a $16.00 price target on the stock. Finally, Piper Sandler boosted their price target on shares of Accolade from $12.00 to $15.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 9th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.80.

Accolade Stock Down 14.1 %

ACCD opened at $7.89 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.35 and a current ratio of 2.35. Accolade has a fifty-two week low of $6.33 and a fifty-two week high of $17.00. The firm’s fifty day moving average is $9.66 and its 200 day moving average is $9.93. The stock has a market cap of $610.76 million, a price-to-earnings ratio of -5.93 and a beta of 2.08.

Accolade (NASDAQ:ACCD) last issued its quarterly earnings data on Thursday, April 25th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. Accolade had a negative net margin of 24.09% and a negative return on equity of 22.57%. The firm had revenue of $124.80 million during the quarter, compared to the consensus estimate of $123.91 million. During the same quarter in the previous year, the firm posted ($0.42) EPS. The company’s revenue for the quarter was up 26.1% compared to the same quarter last year.

Institutional Investors Weigh In On Accolade

Hedge funds and other institutional investors have recently bought and sold shares of the company. BluePath Capital Management LLC purchased a new position in shares of Accolade in the third quarter worth $28,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Accolade in the third quarter worth $28,000. AJOVista LLC acquired a new stake in shares of Accolade in the fourth quarter worth $68,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Accolade in the first quarter worth $87,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Accolade by 84.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,928 shares of the company’s stock worth $126,000 after acquiring an additional 5,455 shares during the period. Hedge funds and other institutional investors own 84.99% of the company’s stock.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.